Disruption of CCR5 signaling in the tumor slows tumor growth through a Treg-mediated mechanism, although disruption of the CCL5/CCR5 axis skews migration of only about 20% of the CD4+ population (less Tregs, more Teffs). The gene discussed is CCL5; the disease is neoplasm.